Search Immortality Topics:

Page 11234..1020..»


Category Archives: Pharmacogenomics

Pain Therapeutics Market Forecasts to 2028 – Advances in Pharmacogenomics & Pharmacogenetics Enabling the Development of Personalized Management – P&T…

DUBLIN, March 13, 2020 /PRNewswire/ -- The "Pain Therapeutics - Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

The worldwide analgesic markets were analyzed for the year 2018 and projected to 2028. Calculations are based on the epidemiology of various painful conditions and the development of analgesic drugs and devices. Unfulfilled needs for analgesics are identified and strategies are outlined to develop markets for analgesic drugs. The report is supplemented with 76 tables, 24 figures, and 600 selected references to the literature.

Over 500 companies have been identified to be involved in developing or marketing pain therapeutics and 173 of these are profiled in the report along with 156 collaborations. These are a mix of pharmaceutical companies and biotechnology companies.

The report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging.

Most of the currently used analgesic drugs fall into the categories of opioids and nonsteroidal antiinflammatory drugs such as COX-2 inhibitors. Non-opioid analgesics include ketamine, a N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include antidepressants and antiepileptic drugs used for the treatment of neuropathic pain. Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery. Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan.

Drug delivery is an important consideration in pain treatment. Controlled release preparations provide a steady delivery of analgesics. Well-known non-injection methods such astransdermal, pulmonary and intranasal application have been used. Topical analgesics and local anesthetics are also available. Devices such as implanted pumps are used for delivery of drugs such as opioids intrathecally (introduction into spinal subarachnoid space by lumbar puncture) in patients with cancer pain.

The wide variety of drugs in development includes opioid receptor ligands, bradykinin antagonists, mPGES-1 inhibitors, glutamate receptor antagonists, substance P and neurokinin receptor antagonists, norepinephrine transporter inhibitors,P2X2 neuron receptor antagonists and nitric oxide-based analgesics. A number of cannabinoids are also in development for pain. Fish-derived tetrodotoxin was initially focused on indication of opiate addiction withdrawal but is found to have an analgesic action as well. Cone shells contain therapeutically useful peptides including the conotoxins, and one such peptide, ziconotide, has been approved. Various cell and gene therapies are also being developed for the management of pain.

Advances in molecular and biological techniques are markedly advancing our undestanding of pain. Understanding the pathophysiology of pain is an important factor in discovery of rational therapies for pain. Advances in pharmacogenomics and pharmacogenetics are enabling the development of personalized approaches to the management of pain.

Key Topics Covered

Executive Summary1. Basic Aspects of Pain2. Assessment of Pain & Analgesics3. Pharmacotherapy of Pain4. Management of Pain5. Drug Delivery for Pain6. Drug Development for Pain7. Safety, Regulatory and Legal Issues of Pain Management8. Pain Markets9. Future of Pain Therapeutics10. Companies Involved in Pain Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/x962ke

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/pain-therapeutics-market-forecasts-to-2028---advances-in-pharmacogenomics--pharmacogenetics-enabling-the-development-of-personalized-management-301022861.html

SOURCE Research and Markets

See the original post here:
Pain Therapeutics Market Forecasts to 2028 - Advances in Pharmacogenomics & Pharmacogenetics Enabling the Development of Personalized Management - P&T...

Posted in Pharmacogenomics | Comments Off on Pain Therapeutics Market Forecasts to 2028 – Advances in Pharmacogenomics & Pharmacogenetics Enabling the Development of Personalized Management – P&T…

BC researchers are exploring the use of genomics to improve drug treatments for people with depression – Yahoo Finance

VANCOUVER, British Columbia, March 13, 2020 (GLOBE NEWSWIRE) -- For people with mental health conditions, finding a medication that works without causing severe side effects is often a matter of trial-and-error. This can contribute to a lower adherence to treatment regimens and poorer health, as well as increased costs to the health care system.

Pharmacogenomics can improve a persons health by helping them know ahead of time whether a drug is likely to be an effective treatment and be safe for them to take without triggering an adverse reaction. This is one of the strongest examples to show how precision health holds real potential to end the trial-and-error approach to therapy.

However, there are still many questions to be answered before there can be wider adoption of pharmacogenomic testing in a clinical setting. In a new $1.5 million project, supported by funding from Genome BC, Genome Canada and the Michael Smith Foundation for Health Research, University of British Columbia researchers, Dr. Stirling Bryan and Dr. Jehannine Austin, are investigating if pharmacogenomic testing should be routinely used in BC for people with depression.

Our goal is to gather the necessary information to assess the improvement in patient health, as well as whether the testing is good value for money for the health system, said Dr. Jehannine Austin. The multidisciplinary team we have assembled includes people with diverse backgrounds and skills, including patient partners with lived experiences.

The work will involve reviewing existing studies to learn from the research of others and collecting BC specific information from the records kept by the health care system. The team will also apply extensive stakeholder engagement, talking to patients, doctors, nurses, pharmacists, counsellors, and others providing care for patients with mental health conditions in BC.

We want to gain insight into the typical experiences of patients, said Dr. Stirling Bryan. This information will be used in a simulation model, where we can count the health benefits to patients and the costs of changing practice to include routine use of pharmacogenomics testing for depression.

Pharmacogenomics shows significant potential for delivering precision health care, said Dr. Ellie Griffith, Sector Director, Health at Genome BC. If the findings indicate that pharmacogenomics testing provides value to both patients and the health care system, this information could be used to bring a positive change to how we care for patients with depression in BC.

MSFHR is committed to partnering on strategic initiatives enabling BC researchers to generate and apply much needed research evidence in areas of high priority to our provinces health system, says Dr. Bev Holmes, President and CEO, Michael Smith Foundation for Health Research.

Genome British Columbia leads genomics innovation on Canadas West Coast and facilitates the integration of genomics into society. A recognized catalyst for government and industry, Genome BC invests in research, entrepreneurship and commercialization in life sciences to address challenges in key sectors such as health, forestry, fisheries and aquaculture, agrifood, energy, mining and environment. Genome BC partners with many national and international public and private funding organizations to drive BCs bioeconomy. http://www.genomebc.ca

Michael Smith Foundation for Health Research (MSFHR), funded by the Province of British Columbia, is BC's health research funding agency. MSFHR helps develop, retain and recruit the talented people whose research improves the health of British Columbians, addresses health system priorities, creates jobs and adds to the knowledge economy. Learn more at http://www.msfhr.org.

Genome Canada is a not-for-profit organization that acts as a catalyst for developing and applying genomics and genomic-based technologies, to create economic and social benefits for Canadians. Genome Canada connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation, and translates discoveries into applications and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries & aquaculture, energy, mining, and the environment. http://www.genomecanada.ca

Story continues

Go here to read the rest:
BC researchers are exploring the use of genomics to improve drug treatments for people with depression - Yahoo Finance

Posted in Pharmacogenomics | Comments Off on BC researchers are exploring the use of genomics to improve drug treatments for people with depression – Yahoo Finance

Sex Differences in Associations Between CYP2D6 Phenotypes and Response | PGPM – Dove Medical Press

Guilherme S Lopes,1,2 Suzette J Bielinski,2 Ann M Moyer,3 John Logan Black III,3 Debra J Jacobson,1 Ruoxiang Jiang,1 Nicholas B Larson,1 Jennifer L St Sauver2

1Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 2Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 3Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

Correspondence: Guilherme S LopesDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USATel +1 507 422 6094Email lopes.guilherme@mayo.edu

Background: Several small studies have previously investigated associations between the cytochrome P450 2D6 (CYP2D6) metabolism and response to opioids. We used a large sample of patients to study associations between CYP2D6 phenotypes and estimated CYP2D6 enzymatic activity scores with pain control and adverse reactions related to codeine and tramadol use. We conducted additional analyses to determine whether our results were consistent among men and women.Methods: We used data from 2,877 participants in the RIGHT Protocol who were prescribed codeine and/or tramadol between 01/01/2005 and 12/31/2017 and who were not prescribed CYP2D6 inhibitors within 1 year prior to the opioid prescription. CYP2D6 phenotype categories were condensed into four groups: (1) Ultra-rapid and Rapid (n = 61), (2) Normal and Intermediate to Normal (n = 1,448), (3) Intermediate and Intermediate to Poor (n = 1,175), and (4) Poor metabolizer status (n = 193). Opioid-related outcomes included indications of poor pain control or adverse reactions related to medication use. We modeled the risk of each outcome using logistic regression, adjusting for age, sex, race, and ethnicity.Results: The results revealed a trend from poor to ultra-rapid and rapid CYP2D6 phenotypes in which the risk of adverse reactions incrementally increased and the risk of poor pain control incrementally decreased. This trend reached statistical significance among female (but not male) participants. Among normal and intermediate to normal metabolizers, a larger proportion of women experienced adverse reactions relative to men.Discussion: We replicated and extended the findings of previous research indicating associations between CYP2D6 phenotypes and response to opioids. In addition, the observed associations were stronger in women than in men. We recommend sex differences to be factored in future research investigating associations between pharmacogenomics and response to medications.

Keywords: opioids, codeine, tramadol, pharmacogenomics, sex differences, CYP2D6

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continue reading here:
Sex Differences in Associations Between CYP2D6 Phenotypes and Response | PGPM - Dove Medical Press

Posted in Pharmacogenomics | Comments Off on Sex Differences in Associations Between CYP2D6 Phenotypes and Response | PGPM – Dove Medical Press

Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts – GlobeNewswire

Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts. While terms of this Agreement are not disclosed, Interpace is an in-network lab with Blue Cross Blue Shield of Massachusetts for all product lines.

Interpace continues to expand in-network agreements and medical coverage for its services with leading National and Regional health plans, while maintaining Medicare coverage through Novitas Solutions.

According to Jack Stover, CEO of Interpace, This contract with Blue Cross Blue Shield of Massachusetts continues our trend of establishing improved reimbursement through participation as an in-network provider. Im pleased to announce that this is the first contract secured by our new VP of Managed Care and Payer Relations, Jeff Salzman.

AboutThyroid Nodules, ThyGeNEXT and ThyraMIR Testing

According to theAmerican Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGenX and ThyraMIR.

ThyGenX and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis for the presence of cancer.

ThyGenX utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGenX and ThyraMIR are covered by both Medicare and Commercial insurers.

AboutInterpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

The Interpace Diagnostics division provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

The Interpace Pharma Solutions division provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Pharma Solutions Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company's filings with the SEC, including without limitation, the Annual Report on Form 10-K and the companys Quarterly Reports filed with the SEC. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:

Interpace DiagnosticsInvestor Relations:Joe Green(646) 653-7030jgreen@edisongroup.comEdison Group

See the rest here:
Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts - GlobeNewswire

Posted in Pharmacogenomics | Comments Off on Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts – GlobeNewswire

Global Precision Medicine Market Review 2016-2019 and Forecast to 2026, Featuring Financials of Key Players – PRNewswire

DUBLIN, Feb. 21, 2020 /PRNewswire/ -- The "Global Precision Medicine Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Precision Medicine market is expected to reach $144.4 billion by 2026, growing at a CAGR of 14.5% from 2018 to 2026.

Some of the factors such as increasing the acceptance rate of gene therapies in developed economies and growing advancements in cancer biology are fuelling market growth. However, high cost of the development and increasing price of genetic testing, is restraining the market growth.

Based on the technology, companion diagnostics segment has witnessed significant growth. Companion diagnostics help healthcare experts to assess the advantages and side-effects or risk of therapeutic products on a patient.

The key vendors mentioned are Teva Pharmaceutical Industries, Tepnel Pharma Services, Quest Diagnostics Incorporated, Qiagen, Pfizer, Novartis, Nanostring Technologies, Medtronic, Laboratory Corporation of America Holdings, Intomics, Hoffmann-La Roche, Ferrer inCode, Eagle Genomics, and Biocrates Life Sciences.

Key Questions Answered in the Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics3.1 Drivers3.2 Restraints

4 Market Environment

5 Global Precision Medicine Market, By Product5.1 Introduction5.2 Services5.3 Instruments5.4 Consumables

6 Global Precision Medicine Market, By Technology6.1 Introduction6.2 Targeted Therapeutics6.3 Molecular Diagnostics6.4 Gene Sequencing6.5 Drug Discovery6.6 Companion Diagnostics6.7 Bioinformatics6.8 Big Data Analytics6.9 Pharmacogenomics (PGX)6.10 Other Technologies

7 Global Precision Medicine Market, By Therapeutics7.1 Introduction7.2 Genetic Tests7.3 Direct to Consumer Tests7.4 Immunology7.5 Gastroenterology7.6 Neurology/Physiatry7.7 Infectious Diseases7.8 Central Nervous System (CNS)7.9 Cardiovascular Disease (CVD)7.10 Cancer/Oncology7.11 Skin Diseases7.12 Respiratory Diseases7.13 Renal Disease7.14 Pulmonary Disease7.15 Ophthalmology7.16 Metabolic Disease7.17 Hematology

8 Global Precision Medicine Market, By End-user8.1 Introduction8.2 Pharmaceutical Companies8.3 Medical Devices8.4 Hospitals8.5 Home Care8.6 Diagnostic Companies8.7 Biotechnology Companies8.8 Healthcare-IT/Big Data firms8.9 Clinical Laboratories

9 Global Precision Medicine Market, By Geography9.1 Introduction9.2 North America9.3 Europe9.4 Asia-Pacific9.5 South America9.6 Middle East & Africa

10 Strategic Benchmarking

11 Vendors Landscape11.1 Teva Pharmaceutical Industries Ltd.11.2 Tepnel Pharma Services11.3 Quest Diagnostics Incorporated11.4 Qiagen N.V.11.5 Pfizer Inc.11.6 Novartis AG11.7 Nanostring Technologies11.8 Medtronic11.9 Laboratory Corporation of America Holdings11.10 Intomics11.11 Hoffmann-La Roche11.12 Ferrer inCode11.13 Eagle Genomics Ltd.11.14 Biocrates Life Sciences AG

For more information about this report visit https://www.researchandmarkets.com/r/i41sk8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See the rest here:
Global Precision Medicine Market Review 2016-2019 and Forecast to 2026, Featuring Financials of Key Players - PRNewswire

Posted in Pharmacogenomics | Comments Off on Global Precision Medicine Market Review 2016-2019 and Forecast to 2026, Featuring Financials of Key Players – PRNewswire

NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of…

Feb. 19, 2020 13:00 UTC

Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance

CULVER CITY, Calif.--(BUSINESS WIRE)-- NantOmics, LLC, the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed study in Breast Cancer Research, a Springer Nature journal, on a novel AI technique in breast cancer. The study reports on a novel deep-learning system of digital pathology images and omics data used together to more precisely identify mechanisms of therapy resistance.

NantOmics scientists trained a deep-neural network on diagnostic slide images from 443 breast tumors that had previously undergone PAM50 subtyping to classify patches of the tumor images into four major molecular subtypes of breast cancer (basal-like, HER2-enriched, luminal A, and luminal B). The algorithm was then validated and demonstrated the capability to establish accurate breast cancer sub-typing in 222 samples from a retained set of tumors. By focusing the neural-networks attention on cancer-rich regions in the diagnostic images, this deep-learning algorithm identifies patient biopsies that are a mixture of different molecular subtypes, a classification that is less definable from molecular pathology techniques. Patients with heterogeneous biopsies such as mixtures of basal-like and luminal disease have a different survival profile than patients with homogeneous disease, and may potentially benefit from a more tailored therapy regimen.

Breast cancer can be subtyped into at least five distinct disease-types with very different prognoses and responses to therapy. These subtypes are characterized as clinically important, yet are typically only achievable by RNA expression profiling, Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth explained. With this AI technique we achieved 87 percent accuracy rate in detecting which patients had basal-like breast cancer (i.e., triple negative breast cancer), one of the most aggressive subtypes, he said.

Our analysis builds on our breadth of advanced machine learning technologies to better support providers in therapeutic decision-making and to improve the capabilities of the underlying molecular analysis technology platforms that we use at NantHealth and NantOmics, said Soon-Shiong. Through the advances of machine vision and augmented intelligence, we have developed a rapid and cost-effective deep-learning technique to unlock the rich information in readily-available diagnostic slide images to define subtypes concordant with their underlying molecular designations.

Breast Cancer Research, a Springer Nature journal, is an international, peer-reviewed online journal publishing original research, reviews, editorials and reports in breast cancer. Breast Cancer Research is published by BMC, an open access publisher that produces over 250 scientific journals and according to its website, is the highest ranked breast cancer focused title in the field.

About NantOmics NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic and machine learning AI capabilities to provide actionable intelligence and molecularly driven decision support for patients and their providers. NantOmics is the first molecular in vitro diagnostics company to accurately identify mutations and true tumor mutation burden (TMB) from proprietary tumor-normal sequencing. The identified mutations and correlative calculation of true TMB, combined with proprietary expression analysis of immuno-oncology biomarkers and novel deep-learning derived digital pathology solutions, establish the framework for the appropriate use of targeted, chemo- and immunotherapies. NantOmics computational analysis engine, an organically grown, scalable, cloud-based infrastructure capable of processing and storing thousands of genomes per day, uses novel AI tools to combine expression analysis with near real-time genomic variance computing to generate precise N of 1 neoepitope vaccine therapies for cancer patients. For more information please visit http://www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About NantHealth NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit http://www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

Forward-Looking Statements: NantHealth This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words expects, anticipates, believes, intends, estimates, plans, will, outlook and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005341/en/

Link:
NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of...

Posted in Pharmacogenomics | Comments Off on NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of…